Immunity against cancer: Lessons learned from melanoma

Current Opinion in Immunology

Volumn 13, Issue 2, 2001, Pages 134-140

  Houghton, Alan N ^a   Gold, Jason S ^a   Blachere, Nathalie E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; GENE MUTATION; HELPER CELL; HUMAN; MELANOMA; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE MODELS, ANIMAL; HUMANS; MALE; MELANOMA; TESTICULAR NEOPLASMS; VACCINATION;

EID: 0035314003     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00195-3     Document Type: Review

References (52)

1. Structure of the gene of tum-transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells
2. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma
3. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
4. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
5. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
6. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
7. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells
8. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
9. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells
10. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
11. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3
12. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
13. Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon
14. Malignant transformation of human melanocytes: Induction of a complete melanoma phenotype and genotype
15. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
16. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression
17. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
18. Human neoplasms elicit multiple specific immune responses in the autologous host
19. Humoral immune responses of cancer patients against 'Cancer-Testis' antigen NY-ESO-1: Correlation with clinical events
20. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA) A2-binding peptide epitopes
21. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
22. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
23. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
24. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets
25. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
26. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product
27. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma
28. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules
29. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
30. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity
31. Tumor immunity and autoimmunity induced by immunization with homologous DNA
32. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
33. Coupling and uncoupling of tumor immunity and autoimmunity
34. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity
35. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
36. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
37. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
38. Fc receptors are required in passive and active immunity to melanoma
39. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
40. + T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
41. + T cells in patients with advanced melanoma
42. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
43. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
44. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions
45. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
46. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
47. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
48. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
49. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
50. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
51. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model
52. Heteroclitic immunization induces tumor immunity